CANTARGIA AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.488 SEK | -6.11% |
|
+8.56% | +20.06% |
| 05-23 | Cantargia Presents New Positive Clinical Data on Nadunolimab Counteracting Chemotherapy Induced Neuropathy | CI |
| 05-21 | Transcript : Cantargia AB, Q1 2024 Earnings Call, May 21, 2024 |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Compared values
| Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CANTARGIA AB | Bio Therapeutic Drugs | -6.11% | +8.56% | +20.06% | -3.40% | -74.79% | 84.03M |  | |  |
Technical Rankings Surperformance
- Stock Market
- Equities
- CANTA Stock
- Charts Cantargia AB
- Comparison Chart
